A Better Future for Bladder Cancer

Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals. With symptoms similar to those of other urinary tract conditions and no reliable screening tests to spot malignancy, patients may experience delays in diagnosis. And these delays can affect survival – almost 90 percent of those diagnosed at stage I survive five years or more, whereas only about 10 percent of those diagnosed at stage IV achieve the same survival. To provide patients with the best possible chances, diagnostic professionals need sensitive, specific tests for bladder cancer – a problem to which URO17™ offers an effective and noninvasive solution.

Acupath Laboratories is happy to partner with The Pathologist on the release of this article showcasing the new biomarker, URO17™.
Find more releases on The Pathologist, here.